Protect – Type 1 Diabetes Study

Enroll Now

Type of Study:

Newly diagnosed adolescents 8-17 years old with Type 1 diabetes

Title of Study:

Placebo-Controlled Study to Evaluate Efficacy and Safety of Teplizumab, in Children and Adolescents, Newly Diagnosed Type 1 Diabetes

Short Title:

PRV-031

Study Length: 18 months

Target Age/Sex: 8 to 17 years old, Male and Female

Benefits:

Participants will receive at no cost: study product, study materials and study-specific procedures

Link: ClinicalTrials.gov